Glucose Homeostasis, Metabolomics and Pregnancy Outcomes After Bariatric Surgery
GLORIA
1 other identifier
observational
190
1 country
8
Brief Summary
The aim of the GLORIA study is to determine whether an altered glucose metabolism (with more hypoglycaemia and glycaemic variability) and altered metabolomics during pregnancy after bariatric surgery contribute to the increased risk for adverse pregnancy outcomes such as small-for-gestational age infants. In addition, the investigators also aim to evaluate whether continuous glucose monitoring (CGM) can be used to diagnose gestational diabetes (GDM).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2023
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2021
CompletedFirst Posted
Study publicly available on registry
October 19, 2021
CompletedStudy Start
First participant enrolled
January 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
May 5, 2026
April 1, 2026
3.6 years
September 20, 2021
April 28, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
mean glycaemia
mean glycaemia measured by CGM
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
Standard deviation of glycaemia
SD measured by CGM
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
Secondary Outcomes (32)
time <54mg/dl
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
glycaemic variability measured by coefficient of variation (CV)
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
glycaemic variability measured by mean amplitude of glucose excursions (MAGE)
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
time <70mg/dl
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
time <63mg/dl
between 6-12 weeks of pregnancy, 18-22 weeks of pregnancy, 24-28 weeks of pregnancy and 30-34 weeks of pregnancy
- +27 more secondary outcomes
Study Arms (2)
pregnant group with bariatric surgery
pregnant women with a history of gastric bypass or sleeve gastrectomy
matched pregnant group without history of bariatric surgery
age-and BMI matched pregnant women without history of bariatric surgery
Interventions
blinded CGM used at 4 different time points in pregnancy
Eligibility Criteria
95 pregnant women with a history of bariatric surgery (RYBG or SG) and 95 age-and BMO matched pregnant women without history of bariatric surgery
You may qualify if:
- Age 18-45 years and with a singleton pregnancy with ultrasound-confirmed gestational age up to 11 weeks and 6 days
- for the group with bariatric surgery: history of gastric bypass (RYBG) or sleeve gastrectomy (SG)
- Participants need to speak and understand Flemish, French or English and have e-mail access.
You may not qualify if:
- multiple pregnancy
- pregnancy ≥12 weeks
- other types of bariatric surgery than RYBG or SG
- known pregestational diabetes
- a physical or psychological disease likely to interfere with the conduct of the study
- medications known to interfere with glucose metabolism.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Antwerpcollaborator
- University Hospital, Ghentcollaborator
- Ziekenhuis Netwerk Antwerpen (ZNA)collaborator
- Onze Lieve Vrouw Hospitalcollaborator
- Imelda Hospital, Bonheidencollaborator
- AZ Sint-Lucas Bruggecollaborator
- General Hospital Groeningecollaborator
- Universitaire Ziekenhuizen KU Leuvenlead
Study Sites (8)
OLV-Aalst-Asse
Aalst, Belgium
UZA
Antwerp, Belgium
ZNA Antwerpen
Antwerp, Belgium
Imelda Bonheiden
Bonheiden, Belgium
AZ St-Jan Brugge
Bruges, Belgium
UZ Gent
Ghent, Belgium
AZ Groeninge Kortrijk
Kortrijk, Belgium
UZ Leuven
Leuven, Belgium
Related Publications (1)
Deleus E, Bochanen N, Ceulemans D, Debunne H, Denys B, Devlieger R, Geerts I, Laenen A, Jochems L, Lannoey E, Lannoo M, Loccufier A, Maes T, Marlier J, Morrens A, Myngheer N, Tierens L, Vandenberghe G, Van den Bruel A, Van den Haute L, Van der Schueren B, Van Pottelbergh I, Benhalima K. Glucose Homeostasis, Metabolomics, and Pregnancy Outcomes After Bariatric Surgery (GLORIA): Protocol for a Multicentre Prospective Cohort Study. J Clin Med. 2025 Jul 7;14(13):4782. doi: 10.3390/jcm14134782.
PMID: 40649156DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Katrien Benhalima, MD PhD
UZ Leuven
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2021
First Posted
October 19, 2021
Study Start
January 25, 2023
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
May 5, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share